Serplulimab is a PD-1 inhibitor immunotherapy drug mainly used to treat certain solid tumors. The currently approved indications in China include: solid tumors with unresectable or metastatic microsatellite instability (MSI-H) or mismatch repair defects (dMMR) (such as colorectal cancer, gastric cancer, etc.); Combination chemotherapy for locally advanced or metastatic squamous non-small cell lung cancer (NSCLC); Combination chemotherapy for extensive stage small cell lung cancer (ES-SCLC); Single drug therapy for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) that has previously received systemic treatment.
1. Detailed explanation of indications
MSI-H/dMMR solid tumor
PD-1 inhibitors work by blocking the pathway through which tumor cells evade the immune system. For solid tumor patients with MSI-H or dMMR, Slulimumab can significantly improve the objective response rate, prolong survival, and has been approved by the National Medical Products Administration (NMPA) of China as a second-line and second-line treatment option.
Non small cell lung cancer and small cell lung cancer
For squamous non-small cell lung cancer, the combination of Sullimumab and chemotherapy (such as paclitaxel+carboplatin) has been approved for first-line treatment, which can improve progression free survival and overall survival.
In extensive stage small cell lung cancer, the combination chemotherapy regimen has also been shown to significantly prolong patient survival.
Head and neck squamous cell carcinoma
For patients with recurrence or metastasis, if they have previously failed platinum based chemotherapy, monotherapy with Slulimumab can be used as a follow-up treatment option.
2. Mechanism of action and medication precautions
Mechanism of action: PD-1 inhibitors restore T cell killing function against tumors by blocking the binding of PD-1 to PD-L1/PD-L2.
Side effects: May cause immune related adverse reactions (such as pneumonia, hepatitis, thyroid dysfunction), requiring regular monitoring and timely treatment.
3. Precautions
Sullimumab is a prescription drug that must be strictly used according to medical advice. Doctors will develop a plan based on the patient's tumor type, molecular characteristics, and physical condition.
Before treatment, it is necessary to complete the detection of PD-L1 expression, MSI/dMMR status, etc. to evaluate applicability.
If serious adverse reactions occur during treatment (such as difficulty breathing, persistent fever), seek medical attention immediately.
It is recommended that patients receive standardized treatment under the guidance of oncologists and participate in personalized follow-up plans.
